Considerations when prescribing trimethoprim-sulfamethoxazole

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 16, 2011, Pages 1851-1858

  Ho, Joanne M W ^a   Juurlink, David N ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CELECOXIB; COTRIMOXAZOLE; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; IBUPROFEN; MEGLITINIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PHENYTOIN; PIROXICAM; REPAGLINIDE; SPIRONOLACTONE; WARFARIN;

ADVERSE DRUG REACTION; ASEPTIC MENINGITIS; BLEEDING; BLOOD DYSCRASIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLEFT PALATE; CONGENITAL HEART DISEASE; CONGENITAL MALFORMATION; CREATININE BLOOD LEVEL; CYTOPENIA; DELIRIUM; DRESS SYNDROME; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG TARGETING; ENVIRONMENTAL EXPOSURE; EOSINOPHILIA; GAIT DISORDER; HEMOLYSIS; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPONATREMIA; INTERSTITIAL NEPHRITIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE DISORDER; LIVER TOXICITY; METHEMOGLOBINEMIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUCOSA INFLAMMATION; MYALGIA; MYOSITIS; NEURAL TUBE DEFECT; NEUROTOXICITY; PRESCRIPTION; RASH; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SMALL FOR DATE INFANT; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREMOR; UROGENITAL TRACT MALFORMATION;

EID: 81055137315     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.111152     Document Type: Review

References (70)

1. McIsaac WJ, Prakash P, Ross S. The management of acute uncomplicated cystitis in adult women by family physicians in Canada. Can J Infect Dis Med Microbiol 2008;19:287-93.
2. Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Recomm Rep 2009;58:1-207.
3. Marshall D, Gough J, Grootendorst P, et al. Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis. J Health Serv Res Policy 2006;11:13-20. (Pubitemid 43117108)
4. Jolles S, Sewell WAC, Leighton C. Drug-induced aseptic meningitis: diagnosis and management. Drug Saf 2000;22:215-26. (Pubitemid 30157582)
5. Slavik RS, Rybak MJ, Lerner SA. Trimethoprim/sulfamethoxazole-induced tremor in a patient with AIDS. Ann Pharmacother 1998;32:189.
6. Dakin LE. Probable trimethoprim/sulfamethoxazole-induced higher-level gait disorder and nocturnal delirium in an elderly man. Ann Pharmacother 2009;43:129-33.
7. Damergis JA, Stoker JM, Abadie JL. Methemoglobinemia after sulfamethoxazole and trimethoprim. JAMA 1983;249:590-1.
8. Koirala J. Trimethoprim-sulfamethoxazole-induced methemoglobinemia in an HIV-infected patient. Mayo Clin Proc 2004; 79: 829-30.
9. Keisu M, Wiholm BE, Palmblad J. Trimethoprim-sulphamethoxazole- associated blood dyscrasias. Ten years' experience of the Swedish spontaneous reporting system. J Intern Med 1990;228:353-60. (Pubitemid 20337478)
10. Myers MW, Jick H. Hospitalization for serious blood and skin disorders following co-trimoxazole. Br J Clin Pharmacol 1997;43: 649-51. (Pubitemid 27283576)
11. Zaman F, Ye G, Abreo KD, et al. Successful orthotopic liver transplantation after trimethoprim-sulfamethoxazole associated fulminant liver failure. Clin Transplant 2003;17:461-4. (Pubitemid 37236121)
12. Kouklakis G, Mpoumponaris A, Zezos P, et al. Cholestatic hepatitis with severe systemic reactions induced by trimethoprim- sulfamethoxazole. Ann Hepatol 2007;6:63-5. (Pubitemid 46407492)
13. Berg PA, Daniel PT. Co-trimoxazole-induced hepatic injury-an analysis of cases with hypersensitivity-like reactions. Infection 1987;15(Suppl 5):S259-64.
14. Thies PW, Dull WL. Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis. Inadvertent rechallenge. Arch Intern Med 1984;144:1691-2. (Pubitemid 14054497)
15. Pusey CD, Saltissi D, Bloodworth L, et al. Drug associated acute interstitial nephritis: clinical and pathological features and the response to high dose steroid therapy. Q J Med 1983;52:194-211. (Pubitemid 14248294)
16. Wanat KA, Anadkat MJ, Klekotka PA. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim- sulfamethoxazole. J Am Acad Dermatol 2009;60:589-94.
17. Gillman MA, Sandyk R. Phenytoin toxicity and co-trimoxazole. Ann Intern Med 1985;102:559. (Pubitemid 15109028)
18. Sivojelezova A, Einarson A, Shuhaiber S, et al. Trimethoprim-sulfonamide combination therapy in early pregnancy. Can Fam Physician 2003;49:1085.
19. Scholl TO, Johnson WG. Folic acid: influence on the outcome of pregnancy. Am J Clin Nutr 2000;71:1295S.
20. Lee M, Bozzo P, Einarson A, et al. Urinary tract infections in pregnancy. Can Fam Physician 2008;54:853.
21. Santos F, Sheehy O, Perreault S, et al. Exposure to anti-infective drugs during pregnancy and the risk of small-for-gestational-age newborns: a case-control study. BJOG 2011 Jul 12. doi: 10.1111/j.1471-0528.2011.03041.x.
22. Wen X, Wang JS, Backman JT, et al. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002;30:631-5. (Pubitemid 34579094)
23. Liegler DG, Henderson ES, Hahn MA, et al. The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 1969;10:849-57.
24. Ferrazzini G, Klein J, Sulh H, et al. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr 1990;117:823-6. (Pubitemid 20382625)
25. Strevel EL, Kuper A, Gold WL. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet Infect Dis 2006; 6:178-82. (Pubitemid 43267643)
26. Niemi M, Kajosaari LI, Neuvonen M, et al. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 2004; 57:441-7. (Pubitemid 38519649)
27. Roustit M, Blondel E, Villier C, et al. Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. Ann Pharmacother 2010; 44: 764-7.
28. Johnson JF, Dobmeier ME. Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. DICP 1990;24:250-1. (Pubitemid 20105820)
29. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8. (Pubitemid 37430270)
30. Schelleman H, Bilker WB, Brensinger CM, et al. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther 2010;88:214-22.
31. Velázquez H, Perazella MA, Wright FS, et al. Renal mechanism of trimethoprim- induced hyperkalemia. Ann Intern Med 1993;119:296.
32. Greenberg S, Reiser IW, Chou SY, et al. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993;119:291-5. (Pubitemid 23319886)
33. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990;323:776-82. (Pubitemid 20303874)
34. Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996;124:316.
35. Mori H, Kuroda Y, Imamura S, et al. Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. Intern Med 2003;42:665-9. (Pubitemid 37021196)
36. Antoniou T, Gomes T, Juurlink DN, et al. Trimethoprim-sulfamethoxazole- induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med 2010;170:1045-9.
37. Marinella MA. Severe hyperkalemia associated with trimethoprim- sulfamethoxazole and spironolactone. Infect Dis Clin Pract 1997;6:257.
38. Schwarz A, Perez-Canto A. Nephrotoxicity of antiinfective drugs. Int J Clin Pharmacol Ther 1998;36:164-7. (Pubitemid 28135038)
39. Alappan R, Buller GK, Perazella MA. Trimethoprim-sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem? Am J Nephrol 1999;19:389-94. (Pubitemid 29301222)
40. Dudley MN, Levitz RE, Quintiliani R, et al. Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. Antimicrob Agents Chemother 1984;26:811-4. (Pubitemid 15181369)
41. Jenkins GC, Hughes DT, Hall PC. A haematological study of patients receiving long-term treatment with trimethoprim and sulphonamide. J Clin Pathol 1970;23:392-6.
42. Heimpel H, Raghavachar A. Hematological side effects of cotrimoxazole. Infection 1987;15(Suppl 5):S248-53.
43. Bourré-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol 2010;37:1416-21.
44. Ermis B, Caner I, Karacan M, et al. Haemolytic anaemia secondary to trimethoprim/sulfamethoxazole use. Thromb Haemost 2003;90:158-9. (Pubitemid 36873874)
45. Ponte CD, Lewis MJ, Rogers JS II. Heinz-body hemolytic anemia associated with phenazopyridine and sulfonamide. DICP 1989;23:140-2. (Pubitemid 19076931)
46. Reinke CM, Thomas JK, Graves AH. Apparent hemolysis in an AIDS patient receiving trimethoprim/sulfamethoxazole: case report and literature review. J Pharm Technol 1996;11:256-62, quiz 293-5.
47. Kiefel V, Santoso S, Schmidt S, et al. Metabolite-specific (IgG) and drug-specific antibodies (IgG, IgM) in two cases of trimethoprim- sulfamethoxazole-induced immune thrombocytopenia. Transfusion 1987;27:262-5. (Pubitemid 17087597)
48. Curtis BR, McFarland JG, Wu GG, et al. Antibodies in sulfonamide- induced immune thrombocytopenia recognize calciumdependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994;84:176-83.
49. Claas FH, van der Meer JW, Langerak J. Immunological effect of co-trimoxazole on platelets. BMJ 1979;2:898-9. (Pubitemid 10242828)
50. Vetrella M, Åstedt B, Barthelmai W, et al. Activity of NADH-and NADPH-dependent methemoglobin reductases in erythrocytes from fetal to adult age. J Klin Wochenschr 1971;49:972-7.
51. Chan TY. Co-trimoxazole-induced severe haemolysis: the experience of a large general hospital in Hong Kong. Pharmacoepidemiol Drug Saf 1997;6:89-92. (Pubitemid 27239409)
52. Lexomboon U, Unkurapiana N. Co-trimoxazole in the treatment of typhoid fever in children with glucose-6-phosphate dehydrogenase deficiency. Southeast Asian J Trop Med Public Health 1978;9:576-80. (Pubitemid 9155474)
53. Markowitz N, Saravolatz LD. Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-deficient population. Rev Infect Dis 1987;9(Suppl 2):S218-29.
54. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982;4:426.
55. Briggs G, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Philadelphia (PA): Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.
56. Czeizel AE, Rockenbauer M, Sørensen HT, et al. The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol 2001;15:637-46. (Pubitemid 34000933)
57. Hernández-Díaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-14. (Pubitemid 32162984)
58. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009;58(RR-11):1-166.
59. Tomasulo P. LactMed-new NLM database on drugs and lactation. Med Ref Serv Q 2007;26:51-8.
60. O'Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980;302:33-5. (Pubitemid 10212234)
61. Schelleman H, Bilker WB, Brensinger CM, et al. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 2008;84:581-8.
62. Fischer HD, Juurlink DN, Mamdani MM, et al. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 2010;170:617-21.
63. Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim/ sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study. Br J Clin Pharmacol 2011;71:544-9.
64. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indianapolis www.drug-interactions.com (accessed 2011 May 2).
65. Wing LM, Miners JO. Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition. Br J Clin Pharmacol 1985;20:482-5. (Pubitemid 16230370)
66. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974;16:348-54.
67. Breckenridge A, Orme M, Wesseling H, et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974;15:424-30.
68. Kosoglou T, Rocci ML Jr, Vlasses PH. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide. Clin Pharmacol Ther 1988;44:467-77. (Pubitemid 18259859)
69. Fujita T, Urban TJ, Leabman MK, et al. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 2006;95:25-36.
70. Katchamart W, Bourre-Tessier J, Donka T, et al. Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. J Rheumatol 2010;37:1422-30.